Search clinical trials for: FTC/TDF and DMPA

Total 2834 results

University of Washington
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

The Kampala Women's Bone Study

Hypoestrogenism | Bone Demineralization | Subclinical Kidney Injury | Bone Microarchitecture

Uganda
Juan A. Arnaiz

Unknown

Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine (RALAM)

AIDS

Spain
Huashan Hospital
The First Affiliated Hospital with Nanjing Medical University; Peking University... and other collaborators

Recruiting

Real-world Study Optimizing Nucleotide-analogues

Hepatitis B, Chronic

China
The HIV Netherlands Australia Thailand Research...
National Health Security Office, Thailand; Swiss HIV Cohort Study

Completed

Second-line Therapy Antiretroviral in Patients Who Failed Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) - Based Regimens

HIV Infections

Thailand
International Antiviral Therapy Evaluation Center
Gilead Sciences

Completed

PREventing Progression of Adipose Tissue Redistribution

HIV Infections

Netherlands
Fundacion SEIMC-GESIDA

Completed

A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study (DREAM)

HIV Infections

Spain
Gilead Sciences

Completed

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

HIV-1 Infection

United States, United Kingdom, Canada, France, Italy, Puerto Rico, Belgium
Yale University

Completed

Project EMPOWERING: Evidence-based PrEP for Justice-Involved Women and Their Risk Networks

HIV Infections

United States
Janssen Scientific Affairs, LLC

Completed

A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain (DEFINE)

HIV-1

United States
University of California, Los Angeles
Gilead Sciences

Completed

Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF) (UCLACAREMITO)

HIV/AIDS | Mitochondrial Alteration | Antiviral Toxicity | Antiviral Drug Adverse Reaction

United States
Auritec Pharmaceuticals
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Safety and Pharmacokinetic Study of HIV Prophylaxis Using Antiretroviral Intravaginal Rings in Healthy Women

Human Immunodeficiency Virus (HIV) Prophylaxis

United States
Gilead Sciences

Completed

Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

HIV-1 Infection

Spain, United States, United Kingdom, Switzerland, Germany, Canada, France, Belgium, Puerto Rico
French National Agency for Research on AIDS and...
Merck Sharp & Dohme LLC

Completed

Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load (EASIER)

HIV Infections

France
Gilead Sciences

Completed

Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)

HIV-1 Infection

United States, Spain, United Kingdom, Netherlands, Germany, Canada, Sweden, Switzerland, Italy, Belgium, Puerto Rico, France
Gilead Sciences

Completed

Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

HIV Infections | HIV

Canada, United States, Spain, Puerto Rico, France, Switzerland, Australia, Germany, United Kingdom, Sweden, Brazil, Austria, Thailand, Netherlands, Belgium, Dominican Republic, Portugal, Italy, Denmark, Mexico
Prism Health North Texas
Merck Sharp & Dohme LLC

Withdrawn

Doravirine and Weight Gain in Antiretroviral Naive (DAWN)

Obesity | Metabolic Syndrome | Body Weight Changes | Human Immunodeficiency Virus | Fasting | Minority Health | ART | BMD

United States
The HIV Netherlands Australia Thailand Research...
Mylan Laboratories

Completed

Therapeutic Drug Monitoring (TDM) in Generic Tenofovir/Lamivudine/Efavirenz

HIV

Thailand
Gilead Sciences

Completed

Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years

HIV-1 Infection

Spain, United Kingdom, Italy, France, Belgium
ANRS, Emerging Infectious Diseases
University of KwaZulu; Africa Centre For Health and Population Studies

Completed

Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence (TasP)

HIV Infection

South Africa
Azienda Ospedaliera San Gerardo di Monza
Gilead Sciences

Completed

Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects (SWEAR)

Quality of Life | HIV-1 Infection | Impaired Cognition | Poor Quality Sleep | Depression/Anxiety

Italy
International AIDS Vaccine Initiative

Completed

A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-risk Populations in Uganda, Africa

HIV Infection

Uganda
International AIDS Vaccine Initiative

Completed

A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-Risk Populations in Kenya, Africa

HIV Infections

Kenya
Gilead Sciences

Completed

Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women (WAVES)

HIV Infections | Acquired Immunodeficiency Syndrome

United States, Thailand, France, Uganda, United Kingdom, Belgium, Portugal, Mexico, Dominican Republic, Italy, Puerto Rico, Russian Federation
University of Washington
National Institute of Mental Health (NIMH); United States Agency for International... and other collaborators

Completed

Partners Demonstration Project of PrEP and ART

HIV Infection

Kenya, Uganda
ANRS, Emerging Infectious Diseases

Completed

First-Line Treatment for HIV-2 (FIT-2)

HIV-2 Infection

Côte D'Ivoire, Burkina Faso, Senegal, Togo
HIV Prevention Trials Network

Completed

HPTN 073 Black Men Who Have Sex With Men (MSM) Pre-Exposure Prophylaxis (PrEP)

HIV

United States
Merck Sharp & Dohme LLC

Completed

Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024) (Impower-024)

HIV Preexposure Prophylaxis

United States, Brazil, France, Japan, South Africa, Thailand, Peru
Felipe Garcia

Completed

Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively Treated

HIV-1 Infection

Spain
Janssen Sciences Ireland UC

Completed

A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects

Immunodeficiency Virus Type 1, Human

United States, France, Poland, United Kingdom, Belgium, Germany, Spain, Canada, Russian Federation, Puerto Rico
Pedro Cahn
Merck Sharp & Dohme LLC

Unknown

RAL+ATV/r in Comparison With TDF/FTC (or 3TC) +ATV/r in HIV Infected Patients (ARTE)

Chronic Infection With HIV

Argentina
Janssen Scientific Affairs, LLC

Completed

A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care

HIV-1

United States
Gilead Sciences

Completed

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis B (China)

HBV | Chronic HBV Infections

China
Gilead Sciences

Completed

Study to Evaluate Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed

Chronic Hepatitis B

United States, Canada, United Kingdom, Hong Kong, Spain, Taiwan, Korea, Republic of, Italy
Gilead Sciences

Completed

Tenofovir DF + Efavirenz (TDF+EFV) Versus Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC) Maintenance Regimen in Virologically Controlled Patients: COOL Trial (COOL)

HIV Infections

France
Gilead Sciences

Completed

Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine

Hepatitis B

Canada, Germany, Turkey, United States, Greece, New Zealand, Hungary, Romania, Bulgaria, Serbia, Austria, Poland, Czech Republic, Spain
Gilead Sciences

Completed

Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e Antigen

HBeAg-positive Chronic Hepatitis B

Hong Kong, Korea, Republic of, United States, Taiwan, United Kingdom, France, Australia, Spain, Bulgaria, Canada, India, Italy, Japan, New Zealand, Poland, Romania, Russian Federation, Singapore, Turkey
Hektoen Institute for Medical Research
National Institute of Mental Health (NIMH)

Completed

Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - PK Study

HIV/AIDS | Gender | Behavior and Behavior Mechanisms

United States
Gilead Sciences

Completed

Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen

HBeAg-negative Chronic Hepatitis B

Hong Kong, United States, United Kingdom, Canada, Australia, Spain, Taiwan, India, Japan, Poland, Romania, Russian Federation, Korea, Republic of, Italy, New Zealand, France, Turkey
Gilead Sciences

Completed

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B (China)

HBV | Chronic HBV Infections

China
Peking Union Medical College

Unknown

Raltegravir-based Antiretroviral Therapy for Resistant HIV-1 Infection

AIDS/HIV PROBLEM

China
Duke University

Completed

Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet (PHI04)

HIV

United States
Gilead Sciences

Completed

Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease.

Chronic Hepatitis B

United States, Canada, Spain, Singapore, Turkey, Germany, France, Taiwan, Greece, Italy, Poland
Gilead Sciences

Completed

Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women

HIV-1 Infection

Russian Federation, United States, Thailand, Uganda, Puerto Rico, Dominican Republic
Stanford University
University of California, Davis; Santa Clara Valley Health & Hospital System

Completed

The Switch Study: The Role of Lamivudine/Emtricitabine (3TC/FTC) in Antiretroviral Regimens

HIV Infections

United States
Centers for Disease Control and Prevention
Gilead Sciences; CDC Foundation

Completed

Sustainable Healthcenter Implementation PrEP Pilot Study (SHIPP)

HIV Preexposure Prophylaxis | HIV Chemoprophylaxis

United States
Philadelphia Fight
Gilead Sciences

Completed

Validation of a Urine Assay to Measure Tenofovir Levels in Patients Taking Tenofovir Alafenamide

Hiv

United States
Göteborg University

Completed

Tenofovir Alafenamide Fumarate (TAF) Effect on Residual Intrathecal Immune Activation

HIV

Sweden
MU-JHU CARE

Recruiting

BONE: STAR (Switching to TAF Based Anti-Retroviral Therapy) Study (BONE:STAR)

Bone Loss

Uganda
University of Maryland, Baltimore

Completed

Phase 1 Pilot Study of an ART Bridging Regimen in Highly Experienced Patients Unable to Achieve Viral Suppression

HIV Infections

United States
Carmen Hidalgo Tenorio
Gilead Sciences

Completed

Study of Bictegravir/Emtricitavine/Tenofovir Alafenamide in HIV-1 Infected naïve Patients Using Test and Treat Stategy Rapid-initiation Model of Care: BIC-NOW Clinical Trial (BIC-NOW) (BIC-NOW)

HIV Infections

Spain

3

Subscribe